Abstract:345 Purpose: CTB006 is a humanized chimeric recombinant anti-human death receptor 5(DR5) agonistic antibody and can specifically bind to DR5. The purpose of this study was to validate the DR 5 expression in human. And investigates the potential of the 89Zr-CTB006 PET/CT to reveal tumor lesions and detect the DR5 expression to screen the DR5 over-expression patients with gastrointestinal cancers.\nPatients and Methods: Patients with gastrointestinal cancer that would undergo surgical operation were enrolled. All patients would undergo 18F-FDG PET/CT and 89Zr-CTB006 PET/CT. 89Zr-CTB006 PET/CT of the first six patients was undertaken 2 hours, 24 hours, 48 hours, 72 hours, 120 hours after 52.77±11MBq 89Zr-CTB006 injection. The other patients underwent 89Zr-CTB006 PET/CT 2 hours, 48 hours, 72 hours after the 89Zr-CTB006 injection. Then the tumor tissues were obtained through surgical operation and the DR5 expression levels were detected by RNAscope.\n Results: Twenty-one patients were enrolled including nine gastric cancers and twelve colorectal cancers. Three patients with colorectal cancers had received chemotherapy or radiotherapy. One patient with gastric cancer withdrew for individual reasons. The biodistribution of 89Zr-CTB006 was evaluated. Except the expected high accumulation in blood, liver and spleen, there was an astonishing finding that the adrenal glands maintained stable high uptake over the whole examination in all patients. The 89Zr-CTB006 was generally high uptake in primary tumor lesions and the metastatic lesions which was more heterogeneous than 18F-FDG and the uptake of 89Zr-CTB006 correlates with that of 18F-FDG significantly(48 h R 0.785, P\u003c0.001;72 hours R 0.791, P\u003c0.001). Both SUVmax of 18F-FDG (SUVmax: 15.26±5.78 vs 6.80±3.35, P 0.04) and 89Zr-CTB006 on 48 hours (SUVmax: 8.94±3.23 vs 4.83±0.51, P 0.005) in previously treated patients were significantly lower than untreated patients with colorectal cancers. The tumor tissue of 9 patients were obtained and the RNAscope results showed that two patients (22.2%) were 2-4 and seven patients (77.8%) were 0-1. The 89Zr-CTB006 uptake in patients with RNAscope results of 2-4 were significantly higher than patients with 0-1 both on 48 hours (SUVmax: 12.35±2.05 vs 4.75±2.21, P 0.005) and 72 hours (SUVmax: 15.48±2.15 vs 5.87±3.18, P 0.005). The tumors with higher uptake than adrenal glands were more likely to be DR5 overexpressed.\nConclusion:89Zr-CTB006 PET/CT can reveal the primary and metastatic tumor lesions with heterogenous uptake and this is the first time to find high uptake in adrenal glands. Higher 89Zr-CTB006 uptake of tumors than adrenal glands is predictive of DR5 over-expression suggesting that the uptake of adrenal glands might be the cutoff value to distinguish DR5 over-expression. Only 22.2% of the patients were DR5 overexpressed, which is much lower than expected. The DR5 expression can be downregulated by chemotherapy and radiotherapy. The study developed a noninvasive approach 89Zr-CTB006 PET/CT to detect the DR5 overexpressed tumors based on the molecular imaging.\nKey words: Death receptor 5; 89Zr-CTB006 PET/CT; Gastrointestinal cancer; molecular imaging. Foundation Support: National Natural Science Foundation of China (81671733, 81871386), Beijing Natural Science Foundation(7171002).\nEthical approval: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients. The clinical study was approved by the Ethics Committee of the Beijing Cancer Hospital (Ethics Approval License: 2018YJZ64)

Analysis of aDR5scFv with Specific Identification and Function.

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity in Vitro and in Vivo

Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis

Structural Basis of LaDR5, a Novel Agonistic Anti-Death Receptor 5 (DR5) Monoclonal Antibody, to Inhibit DR5/TRAIL Complex Formation

[Construction and expression of anti-tumor necrosis factor related apoptosis-inducing ligand receptor death receptor 5 chimeric antibody in eukaryotic cells]

The Construction and Expression of A Novel Chimeric Anti-Dr5 Antibody

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

The Preparation and Tumor Cell Apoptosis-Inducing Activity Assay of Anti-Human DR5 Single-Chain Antibody

Analysis of Trail Receptor Expression Using Anti-Trail Death Receptor-5 Monoclonal Antibodies

Characterization of Single Chain Antibody Against DR5

The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.

The Characteristic of an Anti-Human DR5 Antibody A6

Tumor-cell Specific Cytotoxic Activity of LBY135, a Novel Anti- DR5 Agonistic Antibody

Small-molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells

Preparation, Characterization, and Activity Analysis of Monoclonal Antibodies Against Human Death Receotor 5

Expression and Preparation of Recombinant Human Soluble DR5 and Detection of Its Biological Activity

Preparation and Characterization of A Set of Monoclonal Antibodies to Trail and Trail Receptors Dr4, Dr5, Dcr1, and Dcr2

Induction of Apoptosis in U343 Cell Line by a Novel Anti-Human DR5 Monoclonal Antibody

[Gene Expression and Primary Functional Characterization of Human DR5 Extracellular Fragment].

Induction of tumor cell apoptosis via Fas/DR5.

Validation, Detection & Molecular Imaging Of Death Receptor 5 In Gastrointestinal Cancer Patients